Shengjiang Liu, PH.D., DVM
Advisors and Consultants

Dr. Liu is an experienced biotechnologist, entrepreneur and investor of early stage ventures in high technology and biotechnology.

He is the chief scientist and head (VP) of Pathogen Safety of Product Supply-Biologics, Bayer Pharmaceuticals since 2006. He serves as a director in several startup companies since 2007. He is also an Industrial Advisory Board Member of Bioengineering in Santa Clara University and a mentor of Techcode (Taiku, Mountain View, CA), an active member in BPOG Biophorium (UK), Parental Drug Association (PDA) and World Federation of Hemophilia (WFH).

Dr. Liu was a founder and president of Abmaxis Inc. (acquired by Merck). He was a group leader of Genentch Inc. in 1990s and assistant professor in Nanjing Agricultural University (NAU) where he investigated animal virology and immunology. He discovered rabbit hemorrhagic disease virus (RHDV), rabbit calicivirus (RC) and the new rabbit disease in 1984 when he was in China.

Dr. Liu has been a key player in 33 biologics including recombinant factor VIII (rhFVIII), long acting rhFVIII, therapeutic antibody drug development and 10 biological license approvals in the past 23 years.

Dr. Liu received his Ph.D. of biochemistry from Kansas State University. He completed his post-doctor training with Dr. Arthur Kornberg, Stanford University.

© Copyright AceLink Therapeutics. All rights reserved